Twenty-five research firms currently cover Aptiv, assigning it an average rating of Moderate Buy. Within this cohort, fourteen analysts recommend a Buy rating, seven favor Hold, and four endorse Strong Buy. Over the past year, the consensus one-year price target has risen to $96.63, reflecting upward revisions from Evercore ISI (to $100) and Daiwa Capital Markets (to $100), as well as recent upgrades to Strong Buy from Wall Street Zen and Zacks Research.

In its third-quarter report, Aptiv delivered $2.17 in earnings per share, outperforming the consensus estimate of $1.81 by 20%. Revenues climbed 7.4% year-over-year to $5.21 billion, ahead of analyst forecasts of $5.05 billion. Management reiterated full-year EPS guidance of 7.55–7.85 and set fourth-quarter guidance at 1.60–1.90, implying continued margin expansion and strengthening free cash flow generation.

Institutional investors control approximately 94.2% of Aptiv’s shares. Notable activity in the third quarter included a 12.1% increase in holdings by Hudson Bay Capital Management and a 90.7% stake build by Swiss Life Asset Management. Conversely, Generali Asset Management reduced its position by 19.8%, trimming about 6,554 shares. New positions were established by Saranac Partners and Groupama Asset Management, signaling mixed sentiment among large holders.